Innovative scientific approaches have facilitated significant progress in drug development during recent decades, offering amazing new treatment options to patients across a range of chronic diseases. However, safety and tolerability of drug candidates and newly approved drugs often remain a key concern, leading to labelling restrictions, black box warnings, and withdrawal of otherwise promising innovative medicines.
The TransBioLine project aims to develop novel safety biomarkers that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, providing to the scientific community, industry and patients with detailed data across a large spectrum of advanced safety biomarkers.
6th Consortium Meeting, 24-25th April 2023 – TransBioLine partners gather in Amsterdam
On the 24th and 25th April, more than 50 representatives of TransBioLine partners had the opportunity to meet in Amsterdam during the 6th TransBioLine Consortium Meeting. After sharing the current financial status of the project and the communication activities performed during the last months, an interesting and insightful discussion on [...]
TransBioLine attended the closing meeting of eTRANSAFE
On the 23rd of February, Sophia Samodelov, TransBioLine Project coordinator, participated in the closing meeting of eTRANSAFE Project “Towards a Quantum leap in drug safety assessment”. eTRANSAFE (enhancing translational safety assessment through integrative knowledge management) is an IMI Project intended to develop an integrative data infrastructure and innovative computational methods [...]
New publication from University of Nottingham
Millions of people with rheumatoid arthritis and psoriasis could benefit from Nottingham biomarker research. Nottingham researchers found its side effects are less likely than previously thought and are calling for guidelines affecting the use of methotrexate to be reviewed. Doctors have used the immuno-suppressant since 1947 and around 1.3 million [...]
TransBioLine promises a decisive advance in biomarker discovery, development, validation, regulatory qualification and application, and bring about a fundamental change in the way drug safety is monitored in clinical trials, and toxicities are diagnosed and managed in clinical practice.